top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • 1 day ago
  • 1 min read

03/05/2026










UCB announced agreement to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers (Ref)


UCB announced that it had signed a definitive agreement to acquire Candid Therapeutics, a privately held clinical-stage biotechnology company developing novel T-cell engagers for the treatment of autoimmune and inflammatory diseases.


  • Under the terms of the agreement, UCB would pay US $2 billion upfront plus up to US $200 million in potential milestone payments, with closing expected by end of Q2 / early Q3 2026, subject to customary closing conditions.


  • Candid's lead asset cizutamig (BCMA TCE) was being evaluated in multiple Phase 1 clinical studies across various autoimmune diseases.


  • The acquisition built upon UCB's recently announced transaction with Antengene and reflected a platform-driven strategy in next-generation immunology, expanding UCB's reach across multiple B-cell targets and disease mechanisms.





bottom of page